Протизапальна терапія атеросклеротичних серцево-судинних захворювань
##plugins.themes.bootstrap3.article.sidebar##
TЦя робота ліцензується відповідно до ліцензії Creative Commons Attribution-ShareAlike 4.0 International License.
##plugins.themes.bootstrap3.article.main##
https://orcid.org/0009-0001-3780-3179
Анотація
У дослідженнях з первинної профілактики запалення та гіперліпідемія передбачали майбутні серцево-судинні події з аналогічною точністю. Ці початкові епідеміологічні дані зрештою сприяли клінічним випробуванням, які показали, що протизапальні засоби можуть суттєво знизити частоту серцево-судинних подій без зміни ліпідів крові. Поряд зі зростанням ефективності гіполіпідемічної терапії запалення стало важливим джерелом залишкового серцево-судинного ризику. Ці дані мають значення у виборі додаткових методів лікування зниження серцево-судинного ризику, оскільки вони припускають, що протизапальні методи лікування ще повністю не використані для клінічної допомоги і що зосередження уваги лише на зниженні атерогенних ліпідів навряд чи усуне весь судинний ризик. Це питання набуло більшої актуальності, оскільки колхіцин у низьких дозах став першим протизапальним засобом, схваленим Управлінням з контролю за продуктами та ліками США, для використання як додаткової терапії для зниження ризику рецидиву інфаркту міокарда, інсульту, коронарної реваскуляризації та серцево-судинної смерті. Останні дані свідчать про те, що втручання в запальні механізми ще не повністю використані для користі пацієнта.
##plugins.themes.bootstrap3.article.details##
Ключові слова:
Посилання
Soehnlein O, Libby P. Targeting inflammation in atherosclerosis-from experimental insights to the clinic. Nat. Rev. Drug Discov. 2021;20:589-610. https://doi.org/10.1038/s41573-021-00198-1
Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022. [Online ahead of print] https://doi.org/10.1038/s41577-021-00584-1
Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124:315-327. https://doi.org/10.1161/circresaha.118.313591
Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576-1588. https://doi.org/10.1038/s41591-019-0590-4
Santos-Zas I, Lemarié J, Zlatanova I, Cachanado M, Seghezzi JC, Benamer H, Goube P, Vandestienne M, Cohen R, Ezzo M, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021;12:1483. https://doi.org/10.1038/s41467-021-21737-9
Zhao TX, Sriranjan RS, Tuong ZK, Lu Y, Sage AP, Nus M, Hubsch A, Kaloyirou F, Vamvaka E, Helmy J, et al. Regulatory T-cell response to low-dose interleukin-2 in ischemic heart disease. NEJM Evidence. 2022;1:EVIDoa2100009. https://doi.org/10.1056/EVIDoa2100009
Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576-1588. https://doi.org/10.1038/s41591-019-0590-4
Cochain C, Koch M, Chaudhari SM, Busch M, Pelisek J, Boon L, Zernecke A. CD8+ T cells regulate monopoiesis and circulating Ly6C high monocyte levels in atherosclerosis in mice. Circ Res. 2015;117:244-253. https://doi.org/10.1161/CIRCRESAHA.117.304611
Santos-Zas I, Lemarié J, Tedgui A, Ait-Oufella H. Adaptive immune responses contribute to post-ischemic cardiac remodeling. Front Cardiovasc Med. 2019;5:198. https://doi.org/10.3389/fcvm.2018.00198
Santos-Zas I, Lemarié J, Zlatanova I, Cachanado M, Seghezzi JC, Benamer H, Goube P, Vandestienne M, Cohen R, Ezzo M, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021;12:1483. https://doi.org/10.1038/s41467-021-21737-9
Porsch F, Mallat Z, Binder CJ. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. Cardiovasc Res. 2021;117:2544-2562. https://doi.org/10.1093/cvr/cvab285
Taleb A, Willeit P, Amir S, Perkmann T, Kozma MO, Watzenböck ML, Binder CJ, Witztum JL, Tsimikas S. High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction. J Lipid Res. 2023;64:100391. https://doi.org/10.1016/j.jlr.2023.100391
Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vré E, Esposito B, Vilar J, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207:1579-1587. https://doi.org/10.1084/jem.20100155
Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;19:1273-1280. https://doi.org/10.1038/nm.3284
Farina CJ, Davidson MH, Shah PK, Stark C, Lu W, Shirodaria C, Wright T, Antoniades CA, Nilsson J, Mehta NN. Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024;120:678-680. https://doi.org/10.1093/cvr/cvae057
Roy P, Ali AJ, Kobiyama K, Ghosheh Y, Ley K. Opportunities for an atherosclerosis vaccine: from mice to humans. Vaccine. 2020;38:4495-4506. https://doi.org/10.1016/j.vaccine.2019.12.039
Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278:483-493. https://doi.org/10.1111/joim.12406
Han J-l, Song Y-x, Yao W-j, Zhou J, Du Y, Xu T. Follicle-stimulating hormone provokes macrophages to secrete IL-1β contributing to atherosclerosis progression. J Immunol. 2023;210:25-32. https://doi.org/10.4049/jimmunol.2200475
Liberale L, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res. 2021;117:411-22. https://doi.org/10.1093/cvr/cvaa211
Galozzi P, Baggio C, Bindoli S, Oliviero F, Sfriso P. Development and role in therapy of canakinumab in adult-onset still’s. Front Pharmacol. 2018;9:1074. https://doi.org/10.3389/fphar.2018.01074
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. https://doi.org/10.1056/nejmoa1707914
Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139:1289-1299. https://doi.org/10.1161/circulationaha.118.038010
Ruiz-Limon P, Ortega R, de la Rosa IA, Del Carmen Abalos-Aguilera M, Perez-Sanchez C, et al. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res. 2017;83:87-103. https://doi.org/10.1016/j.trsl.2016.12.003
Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, et al. Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021;77:1845-1855. https://doi.org/10.1016/j.jacc.2021.02.049
Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2021;32:211-222. https://doi.org/10.1681/asn.2020050595
Liberale L, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res. 2021;117:411-22. https://doi.org/10.1093/cvr/cvaa211
Silvis MJ, Fiolet AT, Opstal TS, Dekker M, Suquilanda D, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: a LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93-100. https://doi.org/10.1016/j.atherosclerosis.2021.08.005
Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42:2765-2775. https://doi.org/10.1093/eurheartj/ehab115
Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé MP, Blondeau L, Guertin MC. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37:776-785. https://doi.org/10.1016/j.cjca.2020.10.006J.-
Bouabdallaoui N, Tardif J-C, Waters DD, Pinto FJ, Maggioni AP, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41:4092-4099. https://doi.org/10.1093/eurheartj/ehaa659
Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, et al. Colchicine in Patients with Acute Coronary Syndrome. Circulation. 2020;142:1890-1900. https://doi.org/10.1161/circulationaha.120.050771
D’Entremont M-A, Lee SF, Mian R, Kedev S, Montalescot G, Cornel JH, et al. Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction. Am Heart J. 2024;275:173-182. https://doi.org/10.1016/j.ahj.2024.06.007
Carnicelli AP, Mentz RJ. Sodium-glucose Cotransporter 2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction: the Heart and Kidney Working Better Together. Am Heart Assoc. 2021;322-325. https://doi.org/10.1161/circulationaha.120.052048
La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. CMLS. 2022;79:273. https://doi.org/10.1007/s00018-022-04289-z
Theofilis P , Sagris M, Oikonomou E, Antonopoulos AS, Siasos G. et al. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents. Int Immunopharm. 2022;111:109080. https://doi.org/10.1016/j.intimp.2022.109080
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP. et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42:4947-4960. https://doi.org/10.1093/eurheartj/ehab420
Charles‐Schoeman C, Lee Y-Yin, Shahbazian A, Wang X, Elashoff D, et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol. 2017;9:46-57. https://doi.org/10.1002/art.39833
Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, et al. Serum levels of lipoprotein (a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Clin Exp Rheumatol. 2012;31:415-421. https://doi.org/10.3899/jrheum.111401
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon D, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380:752-762. https://doi.org/10.1056/nejmoa1809798
Singh TP, Skalina T, Nour D, Murali A, Morrison S, et al. A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting. BMC Cardiovasc Disord. 2018;18:1-9. https://doi.org/10.1186/s12872-018-0881-6
Guedes M, Esperança A, Pereira AC, Rego C. What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review. Rev Port Cardiol. 2014;33:727-732. https://doi.org/10.1016/j.repce.2014.06.003
Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart. 2012;98:1543-1545. https://doi.org/10.1136/heartjnl-2012-302249
Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161-2167. https://doi.org/10.1016/s0140-6736(10)60391-1
Antonopoulos AS, Papanikolaou Е, Vogiatzi G, Oikonomou E, Tousoulis D. Anti-inflammatory agents in peripheral arterial disease. Curr Opin Pharm. 2018;39:1-8. https://doi.org/10.1016/j.coph.2017.11.001
Casella IB, Presti C. A new era of medical therapy for peripheral artery disease. J Vasc Bras. 2020;19:e20190056. https://doi.org/10.1590/1677-5449.190056
Silverstein RL. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes “DAMP”. Circulation. 2021;143:62-64. https://doi.org/10.1161/circulationaha.120.051940
Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014;6:258ra143. https://doi.org/10.1126/scitranslmed.3008782
Momtazi-Borojeni AA, Jaafari MR, Afshar M, Banach M, Sahebkar A. PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. Arch Med Sci. 2021;17:1365-1377. https://doi.org/10.5114/aoms/133885
Casula M, Olmastroni E, Boccalari MT, Tragni E, Pirillo A, et al. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharm Res. 2019;143:143-150. https://doi.org/10.1016/j.phrs.2019.03.021
Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017;120:229-243. https://doi.org/10.1161/circresaha.116.308537
Niu Y, Bai N, Ma Y, Zhong P-Y, Shang Y-S, Wang Z.L. Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: A systematic review and meta-analysis. BMC Cardiovasc Disord. 2022;22:84. https://doi.org/10.1186/s12872-022-02525-9
Kwon O, Kang S-J, Kang SH, Lee PH, Yun S-C, et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circ Cardiovasc Imaging. 2017;10: e005934. https://doi.org/10.1161/circimaging.116.005934
Hellberga S, Sippolaa S, Liljenbäckab H, et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr−/−Apob100/100 mice. Atherosclerosis. 2017;263:369-376. https://doi.org/10.1016/j.atherosclerosis.2017.04.004
Puri R, Nissen SE, Shao M, et al. Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. Am J Cardiology. 2014;114(10):1465-1472. https://doi.org/10.1016/j.amjcard.2014.08.009